No Data
No Data
10-Q: Q2 2024 Earnings Report
Express News | NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Express News | NewAmsterdam Pharma Company NV - Achieves Primary Endpoint in Phase 3 Brooklyn Trial
Express News | NewAmsterdam Pharma to Announce Topline Data From Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
Express News | NewAmsterdam Pharma Announces Appointments of Mark C. Mckenna and Wouter Joustra to Its Board of Directors
Express News | NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib Plus Ezetimibe in Patients With Hefh and/or Ascvd or Ascvd Risk Factors
No Data